Enterocolitis in Patients with Cancer Treated with Docetaxel.
Fiche publication
Date publication
avril 2018
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier, Dr VIENOT Angélique, Dr SELMANI Zohair
Tous les auteurs :
Fiteni F, Paillard MJ, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houédé N, Pivot X
Lien Pubmed
Résumé
Enterocolitis is a rare, but serious gastrointestinal complication associated with docetaxel-based chemotherapy in patients with cancer. The incidence, clinical presentation and outcome of enterocolitis in patients with cancer treated with docetaxel-based chemotherapy was assessed in this study Patients and Methods: All patients treated with docetaxel for cancer between January 2010 and December 2014 at the University Hospital of Besançon were identified and their medical records reviewed.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Dose-Response Relationship, Drug, Enterocolitis, chemically induced, Female, Humans, Incidence, Male, Middle Aged, Nausea, chemically induced, Neoplasms, drug therapy, Neutropenia, chemically induced, Retrospective Studies, Taxoids, administration & dosage, Vomiting, chemically induced, Young Adult
Référence
Anticancer Res.. 2018 04;38(4):2443-2446